Therefore, the presence of mutations that interest the signaling genes (such as NRAS, KRAS, PTPN11, CBL, JAK2, FLT3) and IDH1 and IDH2 mutations could lead to the MDS’s progression into AML. This evidence concerns the gene PTPN11 and acute myeloid leukemia.